Profile data is unavailable for this security.
About the company
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
- Revenue in USD (TTM)73.48m
- Net income in USD-108.30m
- Incorporated2011
- Employees223.00
- LocationPersonalis Inc6600 Dumbarton CircleFREMONT 94555United StatesUSA
- Phone+1 (650) 752-1300
- Fax+1 (302) 531-3150
- Websitehttps://www.personalis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | 0.00 | -117.67m | 75.12m | 65.00 | -- | 0.5747 | -- | -- | -3.09 | -3.09 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -56.25 | -30.73 | -63.93 | -32.46 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.04 | -- | -- | -- |
| Bakhu Holdings Corp | 0.00 | -1.92m | 75.33m | 2.00 | -- | -- | -- | -- | -0.0064 | -0.0064 | 0.00 | -0.0325 | 0.00 | -- | -- | 0.00 | -281.75 | -4,391.82 | -- | -- | -- | -- | -- | -- | -- | -8.39 | -- | -- | -- | -- | 33.37 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 76.19m | 9.00 | -- | 3.89 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -64.73m | 76.36m | 41.00 | -- | 0.6106 | -- | -- | -2.82 | -2.82 | 0.00 | 4.19 | 0.00 | -- | -- | 0.00 | -53.65 | -- | -58.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 76.50m | 2.00 | -- | 11.79 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -25.79m | 77.28m | 25.00 | -- | 2.54 | -- | -- | -0.8564 | -0.8564 | 0.00 | 0.7609 | 0.00 | -- | -- | 0.00 | -60.26 | -- | -76.27 | -- | -- | -- | -- | -- | -- | -1,878.67 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Alpha Teknova Inc | 36.68m | -36.78m | 77.56m | 210.00 | -- | 0.8609 | -- | 2.11 | -1.17 | -1.17 | 1.15 | 2.21 | 0.2612 | 2.21 | 8.94 | 174,685.70 | -26.19 | -- | -28.17 | -- | 28.07 | -- | -100.26 | -- | 3.84 | -37.45 | 0.1283 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| Personalis Inc | 73.48m | -108.30m | 78.86m | 223.00 | -- | 0.6006 | -- | 1.07 | -2.25 | -2.25 | 1.53 | 2.56 | 0.2838 | 5.80 | 4.28 | 329,511.20 | -41.83 | -28.84 | -49.51 | -34.72 | 24.78 | 28.65 | -147.38 | -96.01 | 2.89 | -- | 0.0218 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
| LAVA Therapeutics NV | 6.77m | -41.97m | 79.66m | 37.00 | -- | 1.56 | -- | 11.77 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Atara Biotherapeutics Inc | 8.57m | -276.13m | 80.68m | 225.00 | -- | -- | -- | 9.41 | -2.61 | -2.61 | 0.0810 | -0.9322 | 0.0316 | 1.57 | 0.2307 | 38,102.22 | -101.91 | -70.20 | -172.16 | -86.94 | -3.65 | -- | -3,220.88 | -1,559.33 | 0.648 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Passage Bio Inc | 0.00 | -102.06m | 80.71m | 58.00 | -- | 0.6468 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 80.99m | 4.00 | -- | -- | -- | 145.22 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -29.49m | 81.98m | 17.00 | -- | 3.04 | -- | -- | -1.96 | -1.96 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -60.38 | -57.10 | -72.81 | -71.20 | -- | -- | -- | -- | -- | -87.30 | 0.2827 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Data as of May 03 2024. Currency figures normalised to Personalis Inc's reporting currency: US Dollar USD
28.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2024 | 6.07m | 12.01% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.06m | 4.08% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.59m | 3.15% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 1.06m | 2.09% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 977.63k | 1.94% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 840.81k | 1.67% |
| BlackRock Financial Management, Inc.as of 31 Dec 2023 | 523.74k | 1.04% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 520.18k | 1.03% |
| Michigan Department of Treasury (Investment Management)as of 31 Mar 2024 | 493.80k | 0.98% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 465.24k | 0.92% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
